心臟植入器材市場－2025-2030年預測

預計心臟植入設備市場將從 2025 年的 428.45 億美元成長到 2030 年的 611.01 億美元，複合年成長率為 7.36%。

心臟植入設備市場分析

心臟植入醫療器材市場是醫療設備產業的重要組成部分，並因心血管疾病盛行率上升和全球人口老化而持續成長。這些器械，例如心臟節律器、置入式除顫器（ICD）和冠狀動脈支架，滿足了心臟疾病治療的關鍵需求。儘管技術進步和支持性醫療政策推動了市場成長，但高成本仍然是一大挑戰。

本研究檢驗了心臟植入醫療器材市場目前的需求、供應和銷售趨勢，以及近期影響該市場發展的重要因素。研究全面分析了關鍵促進因素、阻礙因素和機遇，並詳細說明了區域產業趨勢、政策和法規，幫助相關人員深入了解法規結構和市場動態。

我們的競爭情報是基於廣泛的二手研究，包括產業協會調查、分析師報告、投資者報告、新聞稿和學術期刊，旨在識別主要企業及其收入貢獻。市場規模採用自下而上和自上而下的方法計算，並透過全球心臟植入設備價值鏈相關人員的第一手資訊進行驗證。我們全面的市場分析整合了各種資訊來源和專有資料集，並運用資料三角驗證技術，提供準確的市場區隔和預測。我們透過分析敘述、圖表和圖形呈現檢驗，以幫助讀者有效率地理解。預計2024年全球市場規模約348億美元，2030年將達542億美元，複合年成長率為7.7%。我們將心律調節器、ICD和冠狀動脈支架的主要製造商列為關鍵參與者。

主要亮點

• 心血管疾病的流行：病例數不斷增加（截至 2024 年，全球有 6 億人受到影響），推動了對心臟植入的需求。
• 人口老化：預計到 2050 年，全球人口將達到 15 億，老齡化人口將推動對心臟設備的需求。
• 技術進步：設備設計的創新正在提高效率並推動市場成長。
• 成本障礙：設備成本高昂，平均售價為 20,000 至 50,000 美元，限制了其在對成本敏感的市場的普及。

成長要素

心血管疾病盛行率的不斷上升（預計到2024年病例數將增加5%）正顯著推動對冠狀動脈支架和植入式心臟復律去顫器（ICD）等醫療器材的需求。人口老化，尤其是在北美和歐洲，導致心臟衰竭和心律不整病例增加，增加了對植入治療的需求。諸如2024年推出的無導線心律調節器等技術創新，正在推動病患療效的改善和器械普及。政府支持措施，例如印度於2024年實施的10億美元“醫療保健普及計劃”，正在提高亞太地區的醫療可近性。

抑制因素

心臟植入醫療器材的高成本，加上相關的植入費用，限制了其在新興市場的普及。嚴格的監管核准要求，例如美國食品藥物管理局（FDA）和歐盟醫療設備法規（MDR）（將於2024年進一步收緊），延長了研發週期。發展中地區有限的健保報銷政策也阻礙了市場滲透。

細分分析

依產品類型分類：受心臟疾病高發生率的影響，冠狀動脈支架將在2024年佔據30%的市場佔有率，穩居榜首。植入式心臟幫浦則因心臟衰竭病例的增加而快速成長。

依應用領域分類：心律不整治療佔比最大，其次是心臟衰竭治療和冠狀動脈疾病治療。

按最終用戶分類：醫院佔比最大，但由於對微創手術的需求不斷成長，門診診所的數量也在增加。

區域分析

到2024年，北美將佔據40%的市場佔有率，這主要得益於美國較高的可支配收入和先進的醫療保健基礎設施。亞太地區正以9.2%的複合年成長率成長，這主要受中國和印度心血管疾病發病率上升以及醫療保健投資增加的推動。歐洲將憑藉其健全的醫療保健體系和研發投入保持成長勢頭。

本報告為業內人士提供關於市場趨勢、監管環境和競爭動態的關鍵洞察。報告重點介紹了先進的醫療器材技術和新興市場機遇，同時也探討了成本和監管方面的挑戰。嚴謹的調查方法，結合一手和二手數據，確保了預測的可靠性，並幫助相關人員理解複雜的市場格局，從而優先考慮在這一重要的醫療設備領域的投資。

本報告的主要優勢：

• 深入分析：取得以客戶群、政府政策和社會經濟因素、消費者偏好、垂直產業和其他細分市場為重點的深入市場洞察，涵蓋主要地區和新興地區。
• 競爭格局：了解主要企業採取的策略舉措，並了解透過正確的策略打入市場的潛力。
• 市場促進因素與未來趨勢：探索動態因素和關鍵市場趨勢，以及它們將如何塑造未來的市場發展。
• 可執行的建議：利用洞察力為策略決策提供訊息，從而在動態環境中開拓新的業務管道和收入來源。
• 受眾範圍廣：對新興企業、研究機構、顧問公司、中小企業和大型企業都有益處且經濟高效。

它是用來做什麼的？

產業與市場洞察、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範及其影響、新產品開發、競爭影響

分析範圍

• 歷史資料（2022-2024 年）和預測資料（2025-2030 年）
• 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
• 競爭對手定位、策略和市場佔有率分析
• 按業務板塊和地區（國家）分類的收入成長和預測分析
• 公司概況（策略、產品、財務資訊、關鍵趨勢等）

目錄

第1章執行摘要

第2章市場概述

• 市場概覽
• 市場定義
• 分析範圍
• 市場區隔

第3章 商業情境

• 市場促進因素
• 市場限制
• 市場機遇
• 波特五力分析
• 產業價值鏈分析
• 政策和法規
• 策略建議

第4章 技術展望

第5章：依產品類型分類的心臟植入設備市場

• 介紹
• 心律調節器
• 心臟再同步治療（CRT）裝置
• 置入式除顫器（ICD）
• 經導管心臟瓣膜（TAVR/TAVI）及外科人工瓣膜
• 心室輔助裝置（VAD/LVAD）
• 心臟監測植入
• 左心耳封堵器（LAA封堵器）
• 冠狀動脈支架
• 人工心臟瓣膜
• 可植入式心臟監測器（ICM）
• 植入式心臟泵
• 線索、生成器和交付系統
• 其他

6. 按分銷類型分類的心臟植入設備市場

• 介紹
• 三級醫院
• 社區醫院
• 門診手術中心
• 心臟診所

7. 各地區心臟植入器材市場

• 介紹
• 北美洲
  • 美國
  • 加拿大
  • 墨西哥
• 南美洲
  • 巴西
  • 阿根廷
  • 其他
• 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 其他
• 中東和非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他

第8章 競爭格局與分析

• 主要企業和策略分析
• 市佔率分析
• 企業合併、協議、商業合作
• 競爭對手儀錶板

第9章：公司簡介

• Medtronic plc
• Abbott Laboratories
• Boston Scientific Corporation
• Edwards Lifesciences Corporation
• Biotronik SE & Co. KG
• LivaNova PLC
• Lepu Medical Technology Co., Ltd.
• Asahi Kasei Corporation（Zoll Medical）
• Abiomed, Inc.
• SynCardia Systems, LLC
• MicroPort Scientific Corporation：

第10章 分析方法

The Cardiac Implant Devices Market is anticipated to rise from USD 42.845 billion in 2025 to USD 61.101 billion by 2030, at a CAGR of 7.36%.

Cardiac Implant Devices Market Analysis

The cardiac implant devices market is a vital segment of the medical device industry, driven by the rising prevalence of cardiovascular diseases and an aging global population. These devices, including pacemakers, implantable cardioverter defibrillators (ICDs), and coronary stents, address critical needs in managing heart conditions. Technological advancements and supportive healthcare policies fuel growth, though high costs pose challenges.

This research examines current trends in demand, supply, and sales, alongside recent developments shaping the cardiac implant devices market. It provides a comprehensive analysis of key drivers, restraints, and opportunities, detailing industry trends, policies, and regulations across geographical regions to equip stakeholders with insights into the regulatory framework and market dynamics.

Competitive intelligence identifies major industry players and their revenue contributions, derived from extensive secondary research, including industry association studies, analyst reports, investor presentations, press releases, and journals. Market size for the overall sector and key segments was determined using bottom-up and top-down methodologies, validated with primary inputs from stakeholders in the global cardiac implant devices value chain. Comprehensive market engineering integrated data from diverse sources and proprietary datasets, employing data triangulation for accurate market breakdown and forecasting. Insights are presented through analytical narratives, charts, and graphics for efficient comprehension. The global market was valued at approximately USD 34.8 billion in 2024 and is projected to reach USD 54.2 billion by 2030, growing at a CAGR of 7.7%. Key players profiled include leading manufacturers of pacemakers, ICDs, and coronary stents.

Key Highlights

• Cardiovascular Disease Prevalence: Rising cases, affecting 600 million globally in 2024, drive demand for cardiac implants.
• Aging Population: A geriatric population of 1.5 billion by 2050 fuels heart disease-related device needs.
• Technological Advancements: Innovations in device design enhance efficacy, boosting market growth.
• Cost Barriers: High device costs, averaging USD 20,000-50,000, limit adoption in cost-sensitive markets.

Growth Drivers

The increasing prevalence of cardiovascular diseases, with a 5% rise in cases in 2024, significantly boosts demand for devices like coronary stents and ICDs. An aging population, particularly in North America and Europe, drives heart failure and arrhythmia cases, necessitating implants. Technological advancements, such as leadless pacemakers introduced in 2024, improve patient outcomes and adoption. Supportive government initiatives, like India's USD 1 billion healthcare access program in 2024, enhance affordability in APAC.

Restraints

High costs of cardiac implant devices, coupled with implantation procedures, restrict access in emerging markets. Stringent regulatory approvals, such as FDA and EU MDR requirements tightened in 2024, increase development timelines. Limited reimbursement policies in developing regions hinder market penetration.

Segmentation Analysis

By Product Type: Coronary stents lead with a 30% share in 2024, driven by coronary heart disease prevalence. Implantable heart pumps grow rapidly due to rising heart failure cases.

By Application: Arrhythmia management dominates, followed by heart failure and coronary artery disease treatments.

By End-User: Hospitals hold the largest share, with outpatient clinics expanding for minimally invasive procedures.

Regional Analysis

North America commands a 40% market share in 2024, driven by high disposable incomes and advanced healthcare infrastructure in the U.S. Asia Pacific grows at a 9.2% CAGR, fueled by rising cardiovascular cases and healthcare investments in China and India. Europe sustains growth through robust healthcare systems and R&D investments.

This report equips industry experts with critical insights into market trends, regulatory landscapes, and competitive dynamics. It highlights opportunities in advanced device technologies and emerging markets while addressing cost and regulatory challenges. The rigorous methodology, blending primary and secondary data, ensures reliable projections, enabling stakeholders to navigate complexities and prioritize investments in this essential medical device sector.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2022 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

By Product Type

• Pacemakers
• Cardiac Resynchronization Therapy (CRT) devices
• Implantable Cardioverter Defibrillator (ICD)
• Transcatheter Heart Valves (TAVR/TAVI) & Surgical Prosthetic Valves
• Ventricular Assist Devices (VADs/LVADs)
• Cardiac Monitoring Implants
• Left Atrial Appendage (LAA) Closure Device
• Coronary Stents
• Prosthetic Heart Valves
• Insertable Cardiac Monitor (ICM)
• Implantable Heart Pump
• Leads, Generators, and Delivery Systems
• Others

By Distribution

• Tertiary Hospitals
• Community Hospitals
• Ambulatory Surgery Centers
• Cardiac Clinics

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CARDIAC IMPLANT DEVICES MARKET BY PRODUCT TYPE

• 5.1. Introduction
• 5.2. Pacemakers
• 5.3. Cardiac Resynchronization Therapy (CRT) devices
• 5.4. Implantable Cardioverter Defibrillator (ICD)
• 5.5. Transcatheter Heart Valves (TAVR/TAVI) & Surgical Prosthetic Valves
• 5.6. Ventricular Assist Devices (VADs/LVADs)
• 5.7. Cardiac Monitoring Implants
• 5.8. Left Atrial Appendage (LAA) Closure Device
• 5.9. Coronary Stents
• 5.10. Prosthetic Heart Valves
• 5.11. Insertable Cardiac Monitor (ICM)
• 5.12. Implantable Heart Pump
• 5.13. Leads, Generators, and Delivery Systems
• 5.14. Others

6. CARDIAC IMPLANT DEVICES MARKET BY DISTRIBUTION

• 6.1. Introduction
• 6.2. Tertiary Hospitals
• 6.3. Community Hospitals
• 6.4. Ambulatory Surgery Centers
• 6.5. Cardiac Clinics

7. CARDIAC IMPLANT DEVICES MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. USA
  • 7.2.2. Canada
  • 7.2.3. Mexico
• 7.3. South America
  • 7.3.1. Brazil
  • 7.3.2. Argentina
  • 7.3.3. Others
• 7.4. Europe
  • 7.4.1. United Kingdom
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Others
• 7.5. Middle East and Africa
  • 7.5.1. Saudi Arabia
  • 7.5.2. UAE
  • 7.5.3. Others
• 7.6. Asia Pacific
  • 7.6.1. China
  • 7.6.2. Japan
  • 7.6.3. India
  • 7.6.4. South Korea
  • 7.6.5. Taiwan
  • 7.6.6. Thailand
  • 7.6.7. Indosneisa
  • 7.6.8. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. Medtronic plc
• 9.2. Abbott Laboratories
• 9.3. Boston Scientific Corporation
• 9.4. Edwards Lifesciences Corporation
• 9.5. Biotronik SE & Co. KG
• 9.6. LivaNova PLC
• 9.7. Lepu Medical Technology Co., Ltd.
• 9.8. Asahi Kasei Corporation (Zoll Medical)
• 9.9. Abiomed, Inc.
• 9.10. SynCardia Systems, LLC
• 9.11. MicroPort Scientific Corporation:

10. RESEARCH METHODOLOGY